Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China

Published:2021-01-01 Issue:1 Volume:24 Page:339-344
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Guan Xin¹²,Li Hongchao¹²,Xiong Xiaomo¹²,Peng Cike³,Wang Ning³,Ma Xiao³,Ma Aixia¹²

Affiliation:

1. School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China

2. Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China

3. Eli Lilly China Drug Development and Medical Affairs Center, Shanghai, China

Funder

Eli Lilly China Drug Development and Medical Affairs Center

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1888743

Reference17 articles.

1. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer;Cancer Management and Research;2024-06

2. Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer;International Journal of Clinical Pharmacy;2024-04-20

3. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer;Journal of Clinical Medicine;2023-12-21

4. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

5. Real-World Utilization, Barriers, and Factors Associated With the Targeted Treatment of Metastatic Colorectal Cancer Patients in China: A Multi-Center, Hospital-Based Survey Study;International Journal of Public Health;2023-07-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3